Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial

• Published in: Critical care (London, England) England), 2019-12, Vol.23 (1), p.428-11, Article 428
• Main Authors: Wang, Anbiao, Cui, Chaomei, Fan, Yiou, Zi, Jie, Zhang, Jie, Wang, Guanglai, Wang, Fang, Wang, Jun, Tan, Qi
• Format: Article
• Language: English
• Subjects: Arrhythmia; Biomarkers - analysis; Cardiac Output, Low - epidemiology; Cardiac Output, Low - etiology; Cardiac Output, Low - prevention & control; Cardiac patients; Cardiac surgery; Cardiac Surgical Procedures - adverse effects; Cardiopulmonary Bypass - adverse effects; Cardiotonic Agents - adverse effects; Cardiotonic Agents - pharmacokinetics; Cardiotonic Agents - therapeutic use; Child health; Child, Preschool; Clinical trials; Congenital diseases; Coronary artery bypass; Critical care; Data collection; Double-Blind Method; Drug dosages; Female; Health aspects; Heart; Heart Defects, Congenital - surgery; Heart failure; Heart surgery; Hemodynamics - drug effects; Humans; Hypotheses; Incidence; Infant; Kaplan-Meier Estimate; Length of Stay; Levosimendan; Low cardiac output syndrome; Male; Medical research; Metabolites; Mortality; Patients; Pediatric; Pediatric cardiology; Pediatrics; Physicians; Postoperative Complications - prevention & control; Prevention; Prospective Studies; Respiration, Artificial; Safety; Simendan - adverse effects; Simendan - pharmacokinetics; Simendan - therapeutic use; Surgery; Treatment Outcome
• ISSN: 1364-8535; 1466-609X; 1466-609X; 1364-8535; 1366-609X
• DOI: 10.1186/s13054-019-2704-2

The administration of levosimendan prophylactically to patients undergoing cardiac surgery remains a controversial practice, and few studies have specifically assessed the value of this approach in pediatric patients. This study therefore sought to explore the safety and efficacy of prophylactic levosimendan administration to pediatric patients as a means of preventing low cardiac output syndrome (LCOS) based upon hemodynamic, biomarker, and pharmacokinetic readouts. This was a single-center, double-blind, randomized, placebo-controlled trial. Patients ≤ 48 months old were enrolled between July 2018 and April 2019 and were randomly assigned to groups that received either placebo or levosimendan infusions for 48 h post-surgery, along with all other standard methods of care. LCOS incidence was the primary outcome of this study. A total of 187 patients were enrolled, of whom 94 and 93 received levosimendan and placebo, respectively. LCOS incidence did not differ significantly between the levosimendan and placebo groups (10 [10.6%] versus 18 [19.4%] patients, respectively; 95% confidence interval [CI] 0.19-1.13; p = 0.090) nor did 90-day mortality (3 [3.2%] versus 4 [4.3%] patients, CI 0.14-3.69, p = 0.693), duration of mechanical ventilation (median, 47.5 h and 39.5 h, respectively; p = 0.532), ICU stay (median, 114.5 h and 118 h, respectively; p = 0.442), and hospital stay (median, 20 days and 20 days, respectively; p = 0.806). The incidence of hypotension and cardiac arrhythmia did not differ significantly between the groups. Levels of levosimendan fell rapidly without any plateau in plasma concentrations during infusion. A multiple logistic regression indicated that randomization to the levosimendan group was a predictor of LCOS. Prophylactic levosimendan administration was safe in pediatric patients and had some benefit to postoperative hemodynamic parameters, but failed to provide significant benefit with respect to LCOS or 90-day mortality relative to placebo. Name of the registry: Safety evaluation and therapeutic effect of levosimendan on the low cardiac output syndrome in patients after cardiopulmonary bypass. ChiCTR1800016594. Date of registration: 11 June 2018. URL of trial registry record: http://www.chictr.org.cn/index.aspx.